The National University of San Marcos (UNMSM) and the Cayetano Heredia Peruvian University (UPCH) will conduct phase 3 clinical trials of a COVID-19 vaccine project.
Through a statement, the Dean of America announced that her School of Medicine, through the Research Group ‘Units of clinical investigators of the infectious and tropical diseases service’, will host these tests to evaluate the safety and protective efficacy of the inactivated vaccine.
This vaccine project, they reported, belongs to the Sinopharm laboratory of China. The trial will begin in mid-September and will involve 3,000 healthy people over 18 years of age.
On the other hand, the Peruvian University Cayetano Heredia, in parallel, will carry out the same test with another 3 000 people, adding a total of 6,000 participants.
For this purpose, the Center for Biomedical and Environmental Technological Research of the UNMSM has implemented a clinical trials unit at the Institute of Tropical Medicine of the Faculty of Medicine that “meets the conditions to conduct trials to test vaccines against COVID-19“.
The UNMSM “It is proud of its researchers, students and research groups that have allowed the university to be at the forefront of work to face this terrible pandemic,” the statement concluded.
Five laboratories to acquire vaccine
The Chinese group Sinopharm It’s one of the five laboratories with which Peru conducts negotiations for the acquisition of vaccines against COVID-19.
On the eve, the president Martin Vizcarra indicated that talks have begun with the UK for the vaccine made by the Oxford University. Vizcarra indicated that by the end of this month the negotiations for the acquisition of this will be completed.
Likewise, negotiations have already begun with Johnson & Johnson of U.S. With them, according to the head of state, the coordination will be closed next September.
In the case of England and the Imperial College, the coordination will end at the end of October. With these three vaccines, between 60 to 70% of the population would be covered, which implies 20 million doses of vaccines, according to the president.
It is also coordinated with the firm Sinovac of China, that through Brazil will begin to produce the vaccine from the last quarter of 2020. The delivery of this vaccine would take place in early 2021.
Newsletter All about the coronavirus
COVID-19 has put everyone on alert. Subscribe to our newsletter All about the coronavirus, where you will find the most relevant daily data in the country and the world on the progress of the virus and the fight against its spread.
‘All about the new coronavirus’. In this program, Dr. Elmer Huerta comments on the data that President Martín Vizcarra has revealed about the acquisition of different vaccines: